Tenecteplase

05/11/2023 - "Our recent pilot study suggests intra-arterial tenecteplase (TNK) during the first pass of endovascular treatment (EVT) seems safe, may increase first-pass reperfusion and good outcome in acute ischaemic stroke (AIS) patients with large-vessel occlusion (LVO). "
02/01/2023 - "In addition, tenecteplase appears to be a safe and effective for the treatment of acute ischemic stroke and is becoming an attractive agent due to its practical administration. "
02/09/2018 - "However, evidence exists that supports the use of other alternatives (tenecteplase), which are also effective in the management of acute ischemic stroke. "
10/01/2017 - "Previous phase 2 trials of tenecteplase in acute ischaemic stroke have shown promising results. "
10/01/2021 - "Tenecteplase has shown promising results in patients with acute ischemic stroke. "

01/01/2023 - "Although thrombolytic use is increasing for acute childhood stroke, there is very limited experience with tenecteplase in children for any indication, and importantly, there are no data on safety, dosing, or efficacy of tenecteplase for childhood stroke. "
01/01/2023 - "Meta-regression demonstrated superior tenecteplase efficacy with increasing stroke severity, however, the results were statistically nonsignificant. "
10/01/2023 - "Urgent need for the introduction of Tenecteplase in Pakistan: A Call to action for improved stroke and Mi Care."
01/01/2023 - "The safety and efficacy of tenecteplase (TNK) in patients with tandem lesion (TL) stroke is unknown. "
01/01/2018 - "Paving the Way for Improved Treatment of Acute Stroke with Tenecteplase."

01/01/2009 - "Hitherto, the small available randomized studies and international clinical registries suggest that pre-hospital TNKase is as effective as primary angioplasty, thus laying the foundations for a new fibrinolytic, TNKase-based strategy as the backbone of reperfusion in acute myocardial infarction."
01/01/2001 - "Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction."
05/01/2003 - "Safety and efficacy of tenecteplase in acute myocardial infarction."
09/01/2009 - "Several large scale Clinical trials of Tenecteplase in acute myocardial infarction (MI) has been done making this drug truly evidence based. "
06/01/2009 - "[An angiographic trial to evaluate the efficacy and safety of tenecteplase in Chinese patients with acute myocardial infarction]."

07/01/2013 - "This study confirms the safety and efficacy of indigenous tenecteplase in Indian patients with STEMI, including high risk subgroups. "
12/01/2005 - "Tenecteplase followed by immediate angioplasty is more effective than tenecteplase alone for people with STEMI. "
11/01/2008 - "CONCLUSION , This data shows that tenecteplase is safe and effective in Indian patients with STEMI and conforms to the international ASSENT-2 trial data."
01/01/2023 - "Whether pharmaco-invasive treatment with half-dose tenecteplase is effective and safe in older patients with STEMI is unknown. "
03/01/2016 - "Two-year follow-up data from the STEPP-AMI study: A prospective, observational, multicenter study comparing tenecteplase-facilitated PCI versus primary PCI in Indian patients with STEMI."

07/01/2014 - "Our study shows that tenecteplase is very effective and safe in the treatment of PE with minimal risk of bleeding in high risk group and intermediate risk and even in selective low risk category group of patients. "
01/01/2021 - "We observed that tenecteplase is effective in 14/15 (93.3%) of our patients, and none of them had any bleeding episodes."
01/01/2001 - "The apparent advantages of tenecteplase (reduced mortality in patients receiving late treatment and reduced incidence of noncerebral bleeding complications) in ASSENT-2 are of interest and merit further attention. "
12/01/2022 - "We assessed the association of tenecteplase with 3-month functional independence and parenchymal hemorrhage (PH) with multivariable logistic models. "
01/01/2022 - "However, tenecteplase is not recommended for patients with intermediate-risk PE because of high bleeding risk. "